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tested for IgH rearrangement, followed by t(4;14) and t(11;14), 
and for deletion 13q, 16q, 17p and hyperdiploidy using probes 
described in Chiecchio et al (2006). We carried out a univariate 
analysis by Fisher exact tests and corrected for multiple testing using 
label swapping permutation using the program PLINK. Genotyping 
was available on 754 patients from the Myeloma IX trial with FISH 
status for hyperdiploidy (355 cases), IgHsplit (306 cases); 13qdel 
(306 cases); p53del (61 cases); del16 (123 cases); t(4;14) (77 cases); 
t(11;14) (90 cases). In addition, we had 1456 UK control datasets 
from the WTCCC (Wellcome Trust Case Control Consortium 
Study) available to us across a subset of the BOAC panel (1100 
SNPs), to examine etiological risk of karyotype subtypes. We found a 
number of significant associations with SNPs in metabolizing genes 
between karyotype subgroups, which might indicate an association 
of exposure to particular toxins with risk of developing a given 
karyotype. We will also report on SNP associations with innate 
immunity and DNA repair genes with karyotype subtypes.
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Introduction and Aims: We had previously reported the 
association of the N QO1*2/*2 polymorphism with a decreased risk 
for multiple myeloma (MM) in Koreans (odds ratio [OR], 0.24; 
95% CI, 0.01-0.68). Materials and Methods: The associations 
of polymorphisms of other metabolizing enzymes (CYP1A1 , 
GSTM1, and GSTT1) with the MM risk were investigated in 
116 Korean MM patients and 176 Korean controls using TaqMan 
Allelic Discrimination and multiplex polymerase chain reaction. 
Results: The ORs for CYP1A1*1/ *2A and CYP1A1*1/ *2B 
genotypes were 0.43 (95% CI, 0.19-0.98) and 0.51 (95% CI, 
0.26-0.98), respectively, which was significantly associated with a 
decreased MM risk. With regard to CYP1A1 alleles, the OR for the 
CYP1A1*2A allele was 0.57 (95% CI, 0.326-0.995), which was 
also significantly associated with a decreased MM risk. However, 
null types of GSTM1 and GSTT1 polymorphisms were not 
associated with the MM risk. These results were different from 
those of a previous report on white patients that suggested the 
association of the GSTT1 polymorphism with an increased MM 
risk and no association of CYP1A1 with the MM risk. Conclusion: 
The associations of polymorphisms of metabolizing enzymes with 
the risk for MM differed between Koreans and white patients, 
suggesting an ethnic variation in the susceptibility to MM.
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Introduction and Aim: Osteoclast inhibitory factor (OCIF), 
that is identical to osteoprotegerin (OPG), has an important role on 
the suppression of osteoclast (OC) activation. The OCIF knockout 
(OCIF-KO) mice show enhanced OC activation in bone, which 
results in diffuse osteolytic or osteopenic changes resembling bone 
changes in myeloma. Therefore, OCIF-KO mice might become a 
bone disease model with persistent stimulation of OC. We analyzed 
whether lenograstim could induce sufficient blood stem cells in 
OCIF-KO mice, in order to elucidate the role of OC activation on 
blood stem cell mobilization. Materials and Methods: OCIF-KO 
C57BL/6 mice were purchased by Snow Brand Milk Company. 
Wild-type C57BL/6 mice were used as control. X-ray photographs 
of hind limb of mice were taken using Sofron SRO-iM50. Histologic 
findings of murine tibia were analyzed by the standard method 
after decalcification. Bone mineral density (BMD; mg/sq cm) was 
measured by dual-energy X-ray absorptiometry (DCS-600, Aloca). 
G-CSF (lenograstim 100 microgram/kg sc, 4days) was used as 
a mobilizer. Blood stem cells were measured using monoclonal 
antibodies reactive against murine CD34, lineage-specific antigens, 
and c-Kit. Cell numbers of blood, marrow, and spleen were counted 
using cell counter (Sysmex F-820). Stem cells after 4-days lenograstim 
were analyzed by flow cytometry (FACS Vintage, Becton-Dickinson). 
Results:  1) Radiographs of hind limbs of mice. OCIF-KO mice 
showed decreased calcified area. 2) Histology of mice. OCIF-KO 
mice showed marked decrease of trabecular bone. 3) BMD. OCIF-
KO mice showed significantly decreased BMD. 4) Blood leukocyte 
count. No significant difference between OCIF-KO mice and wild 
type. 5) Blood stem cell (Lin-, c-Kit+, CD34+) count: In wild type, 
stem cell count (SC-C) showed significant increase after lenograstim 
(0.016% of WBC vs. 0.081%). In OCIF-KO mice, SC-C did not 
show significant increase after lenograstim (0.021% vs. 0.032%). 
Conclusion: Lenograstim-induced blood stem cell mobilization was 
defective in OCIF-KO mice. Further study must be done to clarify 
the mechanism of OC activation or osteopenia on the efficiency of 
lenograstim-induced blood stem cell mobilization.
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Introduction: Expression of cancer-testis (CT) antigens is 
